Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Cash from Operations: 2020-2025

Historic Cash from Operations for Lyell Immunopharma (LYEL) over the last 5 years, with Sep 2025 value amounting to -$28.6 million.

  • Lyell Immunopharma's Cash from Operations rose 18.45% to -$28.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$165.0 million, marking a year-over-year decrease of 5.92%. This contributed to the annual value of -$162.4 million for FY2024, which is 0.79% up from last year.
  • As of Q3 2025, Lyell Immunopharma's Cash from Operations stood at -$28.6 million, which was up 17.07% from -$34.5 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Cash from Operations registered a high of -$25.5 million during Q3 2021, and its lowest value of -$54.7 million during Q1 2025.
  • For the 3-year period, Lyell Immunopharma's Cash from Operations averaged around -$40.4 million, with its median value being -$39.2 million (2023).
  • Per our database at Business Quant, Lyell Immunopharma's Cash from Operations tumbled by 45.55% in 2022 and then grew by 18.45% in 2025.
  • Over the past 5 years, Lyell Immunopharma's Cash from Operations (Quarterly) stood at -$33.2 million in 2021, then decreased by 21.24% to -$40.3 million in 2022, then declined by 0.91% to -$40.6 million in 2023, then dropped by 16.26% to -$47.2 million in 2024, then rose by 18.45% to -$28.6 million in 2025.
  • Its Cash from Operations was -$28.6 million in Q3 2025, compared to -$34.5 million in Q2 2025 and -$54.7 million in Q1 2025.